Compare Corning Incorporated (GLW) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Spyre Therapeutics Inc. Common Stock — how do they compare? Corning Incorporated trades at $136.83 (market cap $127.95B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Corning Incorporated is far larger — about 17× Spyre Therapeutics Inc. Common Stock's market cap, and Corning Incorporated pays a 0.75% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GLW | SYRE | |
|---|---|---|
Market Cap | $127.95B | $7.52B |
Volume | 7,325,250 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $255.79 | $108.92 |
52-Week Low | $78.03 | $22.18 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $134.83B | $6.52B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $140.91, down 4.31% today, amid a bearish technical outlook despite strong fundamentals. The stock shows robust earnings beats in recent quarters and recently secured a significant $3 billion fiber supply agreement with AT&T, positioning it well for AI-driven infrastructure demand. Analyst consensus remains bullish with a $171.25 price target, though technical indicators signal near-term weakness with support at $134.
GLW presents a compelling long-term investment opportunity driven by its leadership in optical communications and materials science, supported by strong revenue growth and improving profit margins. Key risks include ongoing patent litigation and market volatility, but institutional confidence remains high with 57% buy ratings and projected 2026 revenue growth to $17 billion.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
